Reply to: Revisiting Radium-223 in Oligometastatic Castration-Sensitive Prostate Cancer: RAVENS Trial Insights

Phuoc T Tran¹, Jarey H Wang¹, Chad Tang¹+1

• ¹Phuoc T. Tran, MD, PhD, Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD; Phuoc T. Tran, MD, PhD, Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD; Chad Tang, MD, Department of GU Radiation Oncology, MD Anderson Cancer Center, Houston, TX; and Ana P. Kiess, MD, PhD, Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.